Myriad Genetics (Myriad Genetics) Debt-to-Equity

: 0.19 (As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

Myriad Genetics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $16.2 Mil. Myriad Genetics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $135.9 Mil. Myriad Genetics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $783.2 Mil. Myriad Genetics's debt to equity for the quarter that ended in Dec. 2023 was 0.19.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Myriad Genetics's Debt-to-Equity or its related term are showing as below:

MYGN' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.16 Max: 0.32
Current: 0.19

During the past 13 years, the highest Debt-to-Equity Ratio of Myriad Genetics was 0.32. The lowest was 0.01. And the median was 0.16.

MYGN's Debt-to-Equity is ranked better than
54.82% of 197 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.23 vs MYGN: 0.19

Myriad Genetics Debt-to-Equity Historical Data

The historical data trend for Myriad Genetics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myriad Genetics Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.21

0.32

0.10

0.16

0.19

Myriad Genetics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.16	0.19	0.28	0.30	0.19

Competitive Comparison

For the Diagnostics & Research subindustry, Myriad Genetics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Myriad Genetics Debt-to-Equity Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Myriad Genetics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Myriad Genetics's Debt-to-Equity falls into.

Myriad Genetics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Myriad Genetics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(16.2	+	135.9)	/	783.2
	=	0.19

Myriad Genetics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(16.2	+	135.9)	/	783.2
	=	0.19

Myriad Genetics (NAS:MYGN) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Myriad Genetics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Myriad Genetics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Myriad Genetics (Myriad Genetics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Myriad Genetics Inc (NAS:MYGN) » Definitions » Debt-to-Equity

Comparable Companies

TWST NEO VCYT GH OPK LAB FLGT CSTL CDNA SHC TSE:2309 TMO DHR IQV IDXX XSWX:LONN A MTD ICLR ILMN

Traded in Other Exchanges

MYD:Germany

Address

320 Wakara Way, Salt Lake City, UT, USA, 84108

Website

https://www.myriad.com

Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.

Executives

Richard Bryan Riggsbee	officer: Chief Financial Officer	322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Daniel K Spiegelman	director	MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
Heinrich Dreismann	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
Nicole Lambert	officer: Chief Operating Officer	322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Margaret Ancona	officer: SVP, Chief of Staff	322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Pamela Wong	officer: Chief Legal Officer	322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Shereen Solaiman	officer: Chief People Officer	320 WAKARA WAY, SALT LAKE CITY UT 84108
Paul Bisaro	director
Dale Muzzey	officer: Chief Scientific Officer	322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Kevin Richard Haas	officer: Chief Technology Officer	322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Natalie Munk	officer: Chief Accounting Officer	322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Lee Nisley Newcomer	director	264 BUSHAWAY ROAD, WAYZATA MN 55391-1901
Rashmi Kumar	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
Jayne B. Hart	officer: Executive VP Human Resources	320 WAKARA WAY, SALT LAKE CITY UT 84108
Jerry S Lanchbury	officer: Senior V.P. - Research	320 WAKARA WAY, SALT LAKE CITY UT 84108